Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 2/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.34 |
| ▸ | METAP2 | P50579 | 2/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7418539 | 1.00 | METAP1 (0.37) | METAP1ALOX5DPP4SLC1A3SLC1A2 | |
| SCHEMBL1449256 | 1.00 | METAP1 (0.37) | METAP1ALOX5DPP4SLC1A3SLC1A2 | |
| SCHEMBL7375737 | 0.98 | ALOX5 (0.34) | METAP1ALOX5DPP4SLC1A3SLC1A2 | |
| SCHEMBL7375837 | 0.93 | — | — | |
| SCHEMBL7608856 | 0.88 | — | — | |
| SCHEMBL8943205 | 0.80 | CPB2 (0.36) | — | |
| SCHEMBL2640244 | 0.80 | CPB2 (0.36) | — | |
| SCHEMBL21211687 | 0.79 | KDM4E (0.38) | METAP1CTSK | |
| SCHEMBL27534752 | 0.79 | KDM4E (0.38) | METAP1CTSK | |
| SCHEMBL7105061 | 0.78 | METAP1 (0.52) | METAP1ALOX5METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1078002-B1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LAB (US) | 2008-05-21 | — | — | EP | claimed |
| US-7166586-B2 | Sulfonamide lactam inhibitors of FXa and method | BRISTOL MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | claimed |
| US-20040186134-A1 | Sulfonamide lactam inhibitors of FXa and method | O'CONNOR STEPHEN P (US) | 2004-09-23 | — | — | US | claimed |
| US-6716963-B1 | OLIGOPEPTIDES | ABBOTT LABORATORIES | 2004-04-06 | — | — | US | claimed |
| EP-1358178-A2 | SULFONAMIDE LACTAM INHIBITORS OF FACTOR XA | Bristol-Myers Squibb Company (US) | 2003-11-05 | — | — | EP | claimed |
| US-6632795-B1 | Treatment of cancer | BASF AKTIENGESELLSCHAFT (DE) | 2003-10-14 | — | — | US | claimed |
| EP-0981358-B1 | DOLASTATIN-15 DERIVATIVES IN COMBINATION WITH TAXANES | BASF AG (DE) | 2003-05-28 | — | — | EP | claimed |
| WO-2002060894-A2 | SULFONAMIDE LACTAM INHIBITORS OF FACTOR XA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-08 | — | — | WO | claimed |
| EP-1021200-B1 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | BASF AG (DE) | 2002-02-06 | — | — | EP | claimed |
| EP-0674652-B1 | DOLASTATIN ANALOG | BASF AG (DE) | 2000-09-13 | — | — | EP | claimed |
| EP-0642530-A1 | DERIVATIVES OF DOLASTATIN | BASF Aktiengesellschaft (DE) | 1995-03-15 | — | — | EP | claimed |
| WO-1994013695-A1 | DOLOSTATIN ANALOG | BASF AKTIENGESELLSCHAFT (DE) | 1994-06-23 | — | — | WO | claimed |
| WO-1993023424-A1 | DERIVATIVES OF DOLASTATIN | BASF AKTIENGESELLSCHAFT (DE) | 1993-11-25 | — | — | WO | claimed |
| EP-0280610-B1 | DIPEPTIDES, PREPARATION PROCESS AND USE IN DOSING PROTEASES | SERBIO (FR) | 1992-10-21 | — | — | EP | claimed |
| US-5140009-A | Stable against proteolytic enzymes; anticarcinogenic agents; urogenital disorders | TAP PHARMACEUTICALS, INC. (US) | 1992-08-18 | — | — | US | claimed |
| EP-0480918-A1 | REDUCED SIZE LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1992-04-22 | — | — | EP | claimed |
| EP-0480918-A4 | REDUCED SIZE LHRH ANALOGS. | ABBOTT LAB (US) | 1991-06-04 | — | — | EP | claimed |
| EP-0417454-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1991-03-20 | — | — | EP | claimed |
| WO-1989007451-A1 | REDUCED SIZE LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1989-08-24 | — | — | WO | claimed |
| EP-0328089-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1989-08-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186134-A1 | Sulfonamide lactam inhibitors of FXa and method | STS, SULT1E1, F8 | METAP1 2081/4885ALOX5 2859/4885DPP4 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.